RESUMEN
A group of small molecule thienopyrimidine inhibitors of Notum Pectinacetylesterase are described. We explored both 2-((5,6-thieno[2,3-d]pyrimidin-4-yl)thio)acetic acids and 2-((6,7-thieno[3,2-d]pyrimidin-4-yl)thio)acetic acids. In both series, highly potent, orally active Notum Pectinacetylesterase inhibitors were identified.
Asunto(s)
Inhibidores Enzimáticos/farmacología , Esterasas/antagonistas & inhibidores , Fémur/efectos de los fármacos , Osteogénesis/efectos de los fármacos , Pirimidinas/farmacología , Animales , Relación Dosis-Respuesta a Droga , Inhibidores Enzimáticos/síntesis química , Inhibidores Enzimáticos/química , Esterasas/metabolismo , Fémur/anatomía & histología , Fémur/crecimiento & desarrollo , Humanos , Ratones , Estructura Molecular , Pirimidinas/síntesis química , Pirimidinas/química , Relación Estructura-ActividadRESUMEN
A group of small molecule thienochromenes inhibitors of Notum Pectinacetylesterase are described. We developed SAR on three series based on carbon, oxygen and sulfur replacement of the 5-position. In each series, highly potent Notum Pectinacetylesterase inhibitors were identified.
Asunto(s)
Benzopiranos/química , Inhibidores Enzimáticos/química , Esterasas/antagonistas & inhibidores , Animales , Benzopiranos/farmacocinética , Benzopiranos/uso terapéutico , Inhibidores Enzimáticos/farmacocinética , Inhibidores Enzimáticos/uso terapéutico , Esterasas/metabolismo , Fémur/fisiología , Semivida , Humanos , Concentración 50 Inhibidora , Masculino , Ratones , Osteoporosis/tratamiento farmacológico , Osteoporosis/fisiopatología , Unión Proteica , Relación Estructura-ActividadRESUMEN
The structure of LX7101, a dual LIM-kinase and ROCK inhibitor for the treatment of ocular hypertension and associated glaucoma, is disclosed. Previously reported LIM kinase inhibitors suffered from poor aqueous stability due to solvolysis of the central urea. Replacement of the urea with a hindered amide resulted in aqueous stable compounds, and addition of solubilizing groups resulted in a set of compounds with good properties for topical dosing in the eye and good efficacy in a mouse model of ocular hypertension. LX7101 was selected as a clinical candidate from this group based on superior efficacy in lowering intraocular pressure and a good safety profile. LX7101 completed IND enabling studies and was tested in a Phase 1 clinical trial in glaucoma patients, where it showed efficacy in lowering intraocular pressure.
RESUMEN
The discovery of a pyrrolopyrimidine class of LIM-kinase 2 (LIMK2) inhibitors is reported. These LIMK2 inhibitors show good potency in enzymatic and cellular assays and good selectivity against ROCK. After topical dosing to the eye in a steroid induced mouse model of ocular hypertension, the compounds reduce intraocular pressure to baseline levels. The compounds also increase outflow facility in a pig eye perfusion assay. These results suggest LIMK2 may be an effective target for treating ocular hypertension and associated glaucoma.
Asunto(s)
Antihipertensivos/síntesis química , Quinasas Lim/antagonistas & inhibidores , Hipertensión Ocular/tratamiento farmacológico , Pirimidinas/síntesis química , Pirroles/síntesis química , Administración Tópica , Animales , Antihipertensivos/química , Antihipertensivos/farmacología , Glaucoma/tratamiento farmacológico , Glaucoma/fisiopatología , Guanidinas/síntesis química , Guanidinas/química , Guanidinas/farmacología , Técnicas In Vitro , Presión Intraocular/efectos de los fármacos , Ratones , Nitrilos/síntesis química , Nitrilos/química , Nitrilos/farmacología , Hipertensión Ocular/inducido químicamente , Hipertensión Ocular/fisiopatología , Piperazinas/síntesis química , Piperazinas/química , Piperazinas/farmacología , Pirimidinas/química , Pirimidinas/farmacología , Pirroles/química , Pirroles/farmacología , Relación Estructura-Actividad , Porcinos , Urea/análogos & derivados , Urea/síntesis química , Urea/química , Urea/farmacologíaRESUMEN
During nearly a decade of research dedicated to the study of sphingosine signaling pathways, we identified sphingosine-1-phosphate lyase (S1PL) as a drug target for the treatment of autoimmune disorders. S1PL catalyzes the irreversible decomposition of sphingosine-1-phosphate (S1P) by a retro-aldol fragmentation that yields hexadecanaldehyde and phosphoethanolamine. Genetic models demonstrated that mice expressing reduced S1PL activity had decreased numbers of circulating lymphocytes due to altered lymphocyte trafficking, which prevented disease development in multiple models of autoimmune disease. Mechanistic studies of lymphoid tissue following oral administration of 2-acetyl-4(5)-(1(R),2(S),3(R),4-tetrahydroxybutyl)-imidazole (THI) 3 showed a clear relationship between reduced lyase activity, elevated S1P levels, and lower levels of circulating lymphocytes. Our internal medicinal chemistry efforts discovered potent analogues of 3 bearing heterocycles as chemical equivalents of the pendant carbonyl present in the parent structure. Reduction of S1PL activity by oral administration of these analogues recapitulated the phenotype of mice with genetically reduced S1PL expression.
Asunto(s)
Aldehído-Liasas/antagonistas & inhibidores , Enfermedades Autoinmunes/tratamiento farmacológico , Imidazoles/farmacología , Administración Oral , Animales , Inhibidores Enzimáticos/administración & dosificación , Inhibidores Enzimáticos/farmacología , Inhibidores Enzimáticos/uso terapéutico , Imidazoles/administración & dosificación , Imidazoles/uso terapéutico , Recuento de Linfocitos , Ratones , Relación Estructura-ActividadRESUMEN
Tryptase is a serine protease found almost exclusively in mast cells. It has trypsin-like specificity, favoring cleavage of substrates with an arginine (or lysine) at the P1 position, and has optimal catalytic activity at neutral pH. Current evidence suggests tryptase beta is the most important form released during mast cell activation in allergic diseases. It is shown to have numerous pro-inflammatory cellular activities in vitro, and in animal models tryptase provokes broncho-constriction and induces a cellular inflammatory infiltrate characteristic of human asthma. Screening of in-house inhibitors of factor Xa (a closely related serine protease) identified beta-amidoester benzamidines as potent inhibitors of recombinant human betaII tryptase. X-ray structure driven template modification and exchange of the benzamidine to optimize potency and pharmacokinetic properties gave selective, potent and orally bioavailable 4-(3-aminomethyl phenyl)piperidinyl-1-amides.